Keymed Biosciences

2162 · HKEX · China

Public Market Listing

2162HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Keymed Biosciences are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(6 total)
6Total Assets
0Approved
4Phase 3 / Filed
2Phase 1–2 / Early
7Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma
Phase 3
CD38Monoclonal antibody
Multiple Myeloma
Phase 3
TSLPMonoclonal antibody
Chronic Obstructive Pulmonary DiseaseAsthma
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaPrurigo Nodularis
Phase 2
TSLP + IL-13Multispecific antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaChronic Spontaneous Urticaria
Phase 1
Amyloid-beta (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Gamgertamig (CM336)Phase 1/2Multiple Myeloma
Est. primary completion 2026-12 · NCT05299424 · CT.gov ↗
What to watch
2027 (9)
February 2027 (1)
stapokibartPhase 3Atopic Dermatitis
Est. primary completion 2027-02 · NCT07106372 · CT.gov ↗
What to watch
March 2027 (1)
LumrotatugPhase 2IgA Nephropathy
Est. primary completion 2027-03 · NCT06830395 · CT.gov ↗
What to watch
July 2027 (1)
CM512Phase 2Asthma
Est. primary completion 2027-07-21 · NCT07011524 · CT.gov ↗
What to watch
September 2027 (1)
Gamgertamig (CM336)Phase 3Multiple Myeloma (MM)
Est. primary completion 2027-09 · NCT07181239 · CT.gov ↗
What to watch
November 2027 (3)
CM512Phase 3Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Est. primary completion 2027-11 · NCT07807826 · CT.gov ↗
What to watch
LumrotatugPhase 1/2Platelet Transfusion Refractoriness
Est. primary completion 2027-11-16 · NCT06792019 · CT.gov ↗
What to watch
Gamgertamig (CM336)Phase 1/2Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
Est. primary completion 2027-11-18 · NCT07175493 · CT.gov ↗
What to watch
December 2027 (2)
LumrotatugPhase 1/2Aplastic Anemia
Est. primary completion 2027-12 · NCT06791824 · CT.gov ↗
What to watch
CM512Phase 2Atopic Dermatitis (AD)
Est. primary completion 2027-12 · NCT07230483 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
CM512Phase 2Chronic Obstructive Pulmonary Disease
Est. primary completion 2028-03-17 · NCT06980142 · CT.gov ↗
What to watch
May 2028 (1)
CM512Phase 2Chronic Rhinosinusitis With Nasal Polyposis
Est. primary completion 2028-05-31 · NCT07519577 · CT.gov ↗
What to watch
June 2028 (1)
CM512Phase 2Perennial Allergic Rhinitis (PAR)
Est. primary completion 2028-06 · NCT07890350 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Gamgertamig (CM336) + LumrotatugPhase 3Multiple Myeloma (MM)
Est. primary completion 2030-05 · NCT07910903 · CT.gov ↗
What to watch
2032 (2)
April 2032 (1)
stapokibartPhase 2/3Chronic Obstructive Pulmonary Disease
Est. primary completion 2032-04-29 · NCT06547333 · CT.gov ↗
What to watch
May 2032 (1)
stapokibartPhase 2/3Moderate to Severe Asthma
Est. primary completion 2032-05 · NCT05761028 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

August 2026Topline resultCM512Phase 2 of CM512 in chronic rhinosinusitis with nasal polyps (China, NCT06930612) met its primary endpoint
March 2026Filing acceptedstapokibartNMPA accepts stapokibart application in prurigo nodularis
CN, NMPA · Keymed Biosciences · Source ↗
January 2026Filing acceptedstapokibartNMPA accepts stapokibart application in adolescent AD
CN, NMPA · Keymed Biosciences · Source ↗
28 April 2024Topline resultstapokibartPhase III PHECDA (NCT05908032) in seasonal allergic rhinitis met its primary endpoint
Keymed Biosciences Inc. · Source ↗

Financial reports

Quarterly & interim (3)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$69M——$11Mreport ↗

Keymed Biosciences reported revenue of $68.99M, up 809.0% YoY and a quarterly net burn of $10.88M for H1 2025.

Figures only: this period's report disclosed no narrative text

View 2 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-H1$7.6M$46M$355M$47Mreport ↗
2023-H1—$36M——report ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$100M$100M$280M$73Mreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$60M$102M$288M$72Mreport ↗
2023-FY$50M$84M$383M$51Mreport ↗
2022-FY$15M$74M$455M$46Mreport ↗